Malignant Hematology Updates:Venetoclax dosing strategies continue to evolveHMA/Ven + IDH1/2 inhibitors: https://doi.org/10.1200/JCO-25-00640HMA/Ven + revumenib: https://doi.org/10.1200/JCO-25-00914Venetoclax + CPX-351: https://doi.org/10.1002/ajh.27723APOLLO: https://doi.org/10.1200/JCO-25-00535Iland APOLLO editorial: https://doi.org/10.1200/JCO-25-01496ctDNA assessment vs. PET in Large B-Cell Lymphoma: https://doi.org/10.1200/JCO-25-01534